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Abstract
The science and technology of CPR is only just emerging from its
infancy. However, substantial improvements are anticipated,
including the ability of lay rescuers to identify cardiac arrest
promptly, the availability of additional measurements, and
expanded intelligence provided by expanded AEDs with which to
more effectively prompt the rescuer through the resuscitation
procedure. Most important in our view is the ability to maintain
uninterrupted precordial compression. Better timing and better
waveforms for defibrillation are emerging. The recognition of the
importance of postresuscitation myocardial dysfunction and the
selection of better vasopressor agents to minimize the adverse
inotropic and chronotropic actions of adrenergic drugs are also
likely to improve outcomes of CPR.
Introduction
Successful reversal of cardiac arrest is contingent on prompt
identification of the absence of an effective heart beat and
interventions that will restore effective ventilation and
circulation. Typically, cardiopulmonary resuscitation (CPR) is
only successful if it is instituted within 5 min after the heart
stops beating. Survival rates for out-of-hospital cardiac arrest
are remarkably low [1]. Especially in large cities and in rural
communities, survival ranges from less than 2% to 5%, which
projects the magnitude of the problem [2,3]. In communities
in which there is early response by bystanders who initiate
CPR or by minimally trained rescuers, including fire and
police personnel, and in which there is early response by an
effective professional emergency medical response system
such as in Seattle, Washington [4,5] or Rochester,
Minnesota [6], survival from out-of-hospital cardiac arrest may
be increased as much as 10-fold.
Cardiac arrest detector
Among major changes in the guidelines from the American
Heart Association [7], lay rescuers are no longer taught or
expected to perform a ‘pulse check’. The early diagnosis of
cardiac arrest by laypersons is therefore based solely on lack
of cerebral responsiveness and failure to detect breathing.
Accordingly, resuscitation is initially delayed for confirmation
of cardiac arrest. With the introduction of external automated
defibrillators (AEDs) [8] there are even longer delays, and
especially so when a pulseless rhythm prompts repetitive
rhythm analyses by the AED, during which interventions must
be suspended [9]. This prompted the development of a
cardiac arrest detector that is based on impedance
measurements [10]. The cardiac arrest detector prompts the
rescuer to intervene more rapidly with chest compression,
protection of the airway and ventilation – not just
defibrillation. The AED therefore becomes a more compre-
hensive measuring device because it detects and quantifies
both heart beat and breathing, and it provides an estimate of
the cardiac output produced by chest compression. It
therefore expands measurements to beyond those provided
by the ECG, and allows more comprehensive automated
decision making and therefore prompting of the rescuer.
Defibrillation
Perhaps among the greatest advances of the past decade
has been the introduction of AEDs. These devices ‘jump start’
the heart by allowing rapid conversion of ventricular
tachycardia and ventricular fibrillation when applied by
minimally trained laypersons [7]. The results of the recently
published Public Access Defibrillation Study in North
America [11] provides additional evidence of the benefit of
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early defibrillation by lay rescuers in settings in which there is
large public exposure. Unfortunately, the same study
suggested little benefit in home settings. In addition, much
has been learned with respect to the biology and technology,
which will form the basis for improved defibrillation in the
future. Repetitive electrical shocks are injurious to the
arrested heart [12]. Biphasic waveforms have major
advantages over monophasic waveforms and allow lower
energy defibrillation, which minimizes myocardial injury and
the severity of the newly identified condition ‘post-
resuscitation myocardial dysfunction’ [13,14].
Postresuscitation myocardial dysfunction
The global myocardial ischemia of cardiac arrest partially
explains the large fall-off in meaningful survival of victims of
cardiac arrest. As many as 40% of victims are initially
resuscitated, but fewer than an average of 5% leave the
hospital alive and neurologically intact. After resuscitation a
progressive reduction in cardiac output and in myocardial
contractility has been demonstrated, such that the heart
produces lesser systemic and coronary blood flows [15–18].
This form of heart failure is similar to the ‘stunning’ of the
myocardium in settings of acute coronary obstruction [19].
During cardiac arrest there is global myocardial ischemia
during the ‘no-flow’ interval in which the myocardium is not
perfused. Like stunning, the function of the heart is
progressively impaired over an interval of 4 hours, with
gradual recovery over the following days [20]. The severity of
postresuscitation myocardial dysfunction is minimized by
early resuscitation with restoration of an effective rhythm,
cardiac output, and coronary blood flow; by reducing the
numbers and the energy levels of shocks delivered by the
defibrillator; and by the use of biphasic rather than
monophasic waveform shocks [13,14].
Precordial compression
Precordial compression produces between 20% and 25% of
the normal cardiac output. Because blood flow is
preferentially delivered to the coronary and cerebral circuits, it
allows these vulnerable organs to survive. The lesser
importance of ventilation in contrast to the essential role of
maintaining forward blood flow prompted the revision of the
American Heart Association international guidelines in the
year 2000 to reduce interruptions for ventilation from 5/1 to
15/2 [7]. The compression to ventilation ratios were therefore
reduced in adults.
A major shortcoming of cardiac resuscitation following the
introduction of AEDs has been the interruption of precordial
compression, during which there is a decline in coronary
perfusion and an exacerbation of myocardial injury, together
with persistent ectopic ventricular arrhythmias and recurrent
cardiac arrest [9,21]. Precordial compression is also
interrupted following onset of cardiac arrest for endotracheal
intubation. Experimental data suggest that as little as 10 s of
interruption to precordial compression compromises
outcomes. Efforts to improve the forward flow generated by
precordial compression have prompted the use of a series of
manual, pneumatic, and electrically powered mechanical
devices, including the Thumper® (Michigan Instruments Inc.,
Grand Rapids, MI, USA) the CardioPump®, the Pneumatic
Vest®, and the Revivant® Compressor (Revivant Corp.,
Sunnyvale, CA, USA), and re-examination of the potential
benefits of open chest internal cardiac massage [22–25].
These discoveries prompted several new developments at
our Institute. The first of these is the resuscitation blanket,
which isolates the rescuer from electrical shocks, allowing for
continuous chest compression independent of delivery of a
shock [26]. Second, repetitive shocks are minimized by
identifying and reacting to optimal timing of defibrillation [27]
by a technique of amplitude frequency analysis. Finally, we
developed a compact chest compressor so that interruption
to chest compression can be avoided during transport. Such
a device is likely to be essential, not only for transport through
stairways, in ambulances, and through the halls of hospitals,
but also because of the ability to maintain effective and
uninterrupted precordial compression.
Monitoring the effectiveness of precordial
compression
End-tidal carbon dioxide has emerged as a very good
measure for quantifying the ‘cardiac output’ produced by
chest compression [28,29]. Such a monitor detects operator
fatigue during human resuscitation, which occurs as early as
2 min after a rescuer starts chest compression. As an
additional benefit, end-tidal carbon dioxide provides almost
immediate detection of return of spontaneous circulation,
without interrupting chest compression to interpret the ECG
or palpate for a potentially pulsatile rhythm.
Limitations and alternatives to epinephrine
(adrenaline)
Epinephrine has been the vasopressor of choice because of
its  α-adrenergic effects, which increase systemic vascular
resistance and therefore myocardial and cerebral blood flows,
and consequently the success of initial resuscitation.
However, epinephrine also has β-adrenergic effects by which
it increases myocardial oxygen consumption and the severity
of postresuscitation myocardial dysfunction. The β-adrenergic
effects of epinephrine also account for increases in
ventricular ectopy and the recurrence of ventricular
tachycardia and ventricular fibrillation. In addition, epinephrine
produces arteriovenous shunting through the lung, and
therefore causes a very profound although transient reduction
in the arterial oxygen content [30]. Experimentally, when the
β-adrenergic effects of epinephrine are blocked by the rapid
acting  β-adrenergic blocker esmolol, the outcomes of
advanced life support are substantially improved [31].
Optimism that vasopressin would minimize the adverse
effects of epinephrine was not supported by a recently
completed European Multicenter Study [32]. The prolonged289
vasoconstrictor action of vasopressin, we suspect, adversely
effects postresuscitation myocardial dysfunction [18].
More recently, our group’s attention has been focused on
more selective adrenergic agents for treatment of cardiac
arrest. Primary α-adrenergic drugs, including phenylephrine
and methoxamine, have predominant α1-adrenergic actions.
Unfortunately,  α1-adrenergic receptors are desensitized
during the myocardial ischemia of cardiac arrest, such that
these drugs are minimally effective in increasing peripheral
resistance. In addition, α1-adrenergic receptors also reside in
the heart, although to a much lesser extent than β-adrenergic
receptors [33]. Accordingly, α1-agonists also have inotropic
effects that increase the severity of myocardial ischemia. Our
attention has therefore turned to a selective α2-adrenergic
agonist and specifically to α-methylnorepinephrine, which has
yielded significantly better outcomes experimentally because
of its relatively pure peripheral vasopressor action [34,35].
Therapeutic hypothermia after cardiac arrest
Cardiac arrest with widespread cerebral ischemia frequently
leads to severe neurologic impairment. Recent studies have
shown that induced hypothermia for 12—24 hours improves
outcome in patients who are resuscitated from out-of-hospital
cardiac arrest [36,37]. The rapid infusion of large volume, ice-
cold crystalloid fluid results in a significant decrease in median
core temperature from 35.5°C to 33.8°C, and is associated
with beneficial hemodynamic, renal, and acid–base effects.
Further studies are ongoing to improve this technique [38].
Conclusion
Although laboratory research on CPR cannot directly be
applied to clinical management, insights gained in the
laboratory led to the extraordinary discovery of CPR itself by
Kouwenhoven and coworkers [39] and, in our experience,
accounted for essentially every subsequent major advance in
the field, including that in adverse effects of automated
defibrillation [40]. The importance thereof is even greater in
light of the restraints that preclude human studies in the USA
when informed consent of the patient is not possible.
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